Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29975
Title: Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
Authors: Garcia-Garcia, Hector M.
McFadden, Eugene P.
von Birgelen, Clemens
Rademaker-Havinga, Tessa
Spitzer, Ernest
Kleiman, Neal S.
Cohen, David J.
Kennedy, Kevin F.
Camenzind, Edoardo
Mauri, Laura
Steg, Philippe Gabriel
Wijns, William
Silber, Sigmund
van Es, Gerrit-Anne
Serruys, Patrick W.
Windecker, Stephan
Cutlip, Donald
VRANCKX, Pascal 
Issue Date: 2019
Publisher: ELSEVIER SCIENCE INC
Source: JACC-CARDIOVASCULAR INTERVENTIONS, 12(19), p. 1954-1962
Abstract: OBJECTIVES This study sought to explore the association between biomarker elevation, with creatine kinase-myocardial band (CK-MB) or cardiac troponin (cTn), following percutaneous coronary intervention (PCI) and mortality in patients undergoing PCI for stable angina with normal baseline values. BACKGROUND Several studies have shown a strong association between post-PCI CK-MB elevation and subsequent mortality. However, the prognostic significance of troponin elevation following coronary intervention is still debated. METHODS Patient-level data from 5 contemporary coronary stent trials and 1 large registry were pooled. Mortality of patients with stable angina, with normal baseline biomarkers, was compared between patients with and those without different cutoff values of cTn and CK-MB. RESULTS A total of 13,452 patients were included in this pooled analysis. The overall percentage of patients with elevated biomarkers following PCI was 23.9% for CK-MB and 68.4% for cTn. In the patient cohort for whom both assays were available (n = 8,859), 2.4% had both CK-MB >= 5 x the upper limit of normal (ULN) and cTn >= 35 x ULN, while 92% had both CK-MB <5 x ULN and cTn <35 x ULN. Among patients with CK-MB >= 5 x ULN (n = 315), 212 (67.3%) also had cTn >= 35 x ULN. Conversely, 390 of patients (64.8%) who had cTn >= 35 x ULN did not have CK-MB >= 5 x ULN. A total of 259 patients (1.9%) died at 1 year; 20 (7.7%) had CK-MB >= 5 x ULN, and 23 (8.8%) had cTn >= 35 x ULN. In the Cox multivariate analysis, in which the CK-MB and cTn ratios post-procedure were forced into the model, age, prior myocardial infarction, lesion complexity, hyperlipidemia, and CK-MB ratio (>= 10) post-procedure were associated with increased 1-year mortality. CONCLUSIONS Following elective PCI in patients in stable condition treated with second-generation drug-eluting stent, CK-MB and cTn elevations remain common. After multivariate adjustment, there was an increased mortality rate with elevation of CK-MB after PCI, whereas cTn elevation was not independently associated with mortality at 1 year. (C) 2019 by the American College of Cardiology Foundation.
Notes: [Garcia-Garcia, Hector M.; Rademaker-Havinga, Tessa; Spitzer, Ernest; van Es, Gerrit-Anne] Cardialysis, Rotterdam, Netherlands. [Garcia-Garcia, Hector M.] MedStar Washington Hosp Ctr, Intervent Cardiol, Washington, DC USA. [McFadden, Eugene P.] Cork Univ Hosp, Intervent Cardiol, Cork, Ireland. [von Birgelen, Clemens] Med Spectrum Twente, Dept Cardiol, Thoraxctr Twente, Enschede, Netherlands. [Spitzer, Ernest] Erasmus MC, Thoraxctr, Dept Cardiol, Rotterdam, Netherlands. [Kleiman, Neal S.] Houston Methodist DeBakey, Intervent Cardiol, Houston, TX USA. [Cohen, David J.; Kennedy, Kevin F.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Camenzind, Edoardo] Univ Geneva, Geneva, Switzerland. [Mauri, Laura] Brigham & Womens Hosp, Div Cardiovasc Med, Baim Inst Clin Res, 75 Francis St, Boston, MA 02115 USA. [Mauri, Laura] Harvard Med Sch, Boston, MA 02115 USA. [Steg, Philippe Gabriel] Univ Paris Diderot, Dept Cardiol, INSERM, FACT,DHU FIRE,U1148, Paris, France. [Steg, Philippe Gabriel] Royal Brompton Hosp, Imperial Coll, Natl Heart & Lung Inst, London, England. [Wijns, William] Onze Lieve Vrouw Hosp, Cardiol Dept, Cardiovasc Res Ctr Aalst, Aalst, Belgium. [Silber, Sigmund] Heart Ctr Isar, Dept Cardiol, Munich, Germany. [Serruys, Patrick W.] Imperial Coll London, Ctr Int Cardiovasc Hlth, London, England. [Windecker, Stephan] Bern Univ Hosp, Bern, Switzerland. [Cutlip, Donald] Baim Inst Clin Res, Boston, MA USA. [Cutlip, Donald] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vranckx, Pascal] Jessa Ziekenhuis, Hartctr Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium. [Vranckx, Pascal] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.
Keywords: cardiac troponin; CK-MB; drug-eluting stent; percutaneous coronary intervention; mortality;cardiac troponin; CK-MB; drug-eluting stent; percutaneous coronary intervention; mortality
Document URI: http://hdl.handle.net/1942/29975
ISSN: 1936-8798
e-ISSN: 1876-7605
DOI: 10.1016/j.jcin.2019.07.014
ISI #: 000489226100015
Rights: 2019 by the American College of Cardiology Foundation. Published by Elsevier.
Category: A1
Type: Journal Contribution
Validations: ecoom 2020
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
garcia-garcia2019.pdf
  Restricted Access
Published version697.26 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

7
checked on Sep 7, 2020

WEB OF SCIENCETM
Citations

47
checked on Jul 27, 2024

Page view(s)

122
checked on Jul 20, 2022

Download(s)

104
checked on Jul 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.